Milestone Pharmaceuticals Reports Q1 2026 Results as CARDAMYST Launch Gains Early Prescriber Traction
Milestone Pharmaceuticals Reports Q1 2026 Results as CARDAMYST Launch Gains Early Prescriber Traction
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) reported its first-quarter 2026 results, highlighting the early commercial launch of CARDAMYSTâĒ (etripamil) nasal spray for paroxysmal supraventricular tachycardia, or PSVT.
The company said healthcare professionals have responded positively during the first stage of the launch. Management pointed to growing prescription activity, broader physician awareness, and new formulary coverage as important signs that CARDAMYST is beginning to build momentum in the U.S. market.
Q1 2026 Financial Results
For the quarter ended March 31, 2026, Milestone reported net product revenue of approximately $238,000. The company also posted a net loss of $26.1 million, or $0.20 per share. Seeking Alphaâs earnings summary showed that revenue came in below analyst expectations, while EPS also missed consensus estimates.
Milestone ended the quarter with about $184.2 million in cash, cash equivalents, and short-term investments, which management said should support operations into the second half of 2027.
CARDAMYST Launch Shows Early Progress
CARDAMYST is Milestoneâs lead commercial product. It is an FDA-approved nasal spray designed to help adults convert acute symptomatic PSVT episodes back to normal sinus rhythm. The drug is positioned as a self-administered treatment option for patients who experience sudden episodes of rapid heartbeat.
During the earnings call, executives said the launch is still in its early phase, but they described the first commercial indicators as encouraging. Reports showed more than 600 prescriptions filled and more than 400 unique healthcare providers writing prescriptions by the end of April.
The company believes the breadth of early prescribers may be a useful signal for future adoption. Rather than depending on only a small group of doctors, CARDAMYST appears to be reaching a wider base of cardiologists and other healthcare professionals.
Express Scripts Coverage Expands Patient Access
One of the most important updates was Milestoneâs progress on payer access. The company secured national formulary coverage through Express Scripts, helping improve commercial access for insured patients. Milestone previously announced that CARDAMYST had become available on Express Scripts commercial national formularies.
This matters because new therapies often face adoption barriers when insurance coverage is limited. Broader formulary access can make it easier for physicians to prescribe the product and for patients to receive it at a more manageable cost.
Management Focuses on Commercial Execution
Chief Executive Officer Joseph Oliveto said the company was encouraged by the first quarter of CARDAMYST sales and by the early reaction from healthcare professionals. He emphasized that the launch is still developing, but the company views initial physician interest as a positive foundation.
Commercial Chief Lorenz Muller also discussed the companyâs efforts to educate physicians, support patient access, and increase awareness of CARDAMYST as a treatment option for PSVT episodes.
Operating Expenses Rise During Launch Phase
Milestoneâs expenses increased as the company invested in commercial infrastructure. Commercial-related expenses rose as Milestone supported sales, marketing, market access, and medical education efforts tied to CARDAMYST.
This is common for a company moving from development into commercialization. However, investors will likely watch closely to see whether prescription growth can begin to scale meaningfully against the companyâs spending base.
AFib-RVR Program Adds Pipeline Opportunity
Beyond PSVT, Milestone is also advancing etripamil in atrial fibrillation with rapid ventricular rate, known as AFib-RVR. The company has started a Phase 3 registration program in this indication, which could expand the long-term commercial opportunity if successful.
AFib-RVR represents a separate cardiovascular condition with a large patient population. Milestoneâs strategy is to build CARDAMYST first in PSVT while also exploring whether etripamil can serve additional heart rhythm needs.
Investor Reaction Remains Mixed
Although management sounded optimistic about the launch, the financial results showed that Milestone is still in an early revenue stage. Revenue remained modest, and the quarterly net loss reflected continued investment in commercialization and clinical development.
For investors, the key question is whether CARDAMYST can move from early adoption to sustained prescription growth. Future quarters will likely be judged by prescription trends, payer coverage, refill behavior, physician adoption, and progress in the AFib-RVR program.
Outlook
Milestoneâs Q1 2026 update shows a company at an important transition point. CARDAMYST is now commercially available, prescriber activity is increasing, and payer access is improving. At the same time, the company must prove that early interest can turn into stronger revenue growth.
The next several quarters will be critical. If Milestone can expand physician adoption, improve patient access, and continue building real-world confidence in CARDAMYST, the product could become a more meaningful contributor to the companyâs business.
Overall, Milestone Pharmaceuticalsâ first-quarter report presented a story of early commercial progress, heavy investment, and cautious optimism as the company works to establish CARDAMYST in the cardiovascular treatment market.
#SlimScan #GrowthStocks #CANSLIM